These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24285547)

  • 81. Molecular Pathology of Gliomas.
    Galbraith K; Snuderl M
    Clin Lab Med; 2024 Jun; 44(2):149-159. PubMed ID: 38821638
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
    Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
    J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma.
    López G; Oberheim Bush NA; Berger MS; Perry A; Solomon DA
    Acta Neuropathol Commun; 2017 May; 5(1):38. PubMed ID: 28506301
    [No Abstract]   [Full Text] [Related]  

  • 84. Distinct molecular profile of diffuse cerebellar gliomas.
    Nomura M; Mukasa A; Nagae G; Yamamoto S; Tatsuno K; Ueda H; Fukuda S; Umeda T; Suzuki T; Otani R; Kobayashi K; Maruyama T; Tanaka S; Takayanagi S; Nejo T; Takahashi S; Ichimura K; Nakamura T; Muragaki Y; Narita Y; Nagane M; Ueki K; Nishikawa R; Shibahara J; Aburatani H; Saito N
    Acta Neuropathol; 2017 Dec; 134(6):941-956. PubMed ID: 28852847
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
    Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
    Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas.
    Gianno F; Antonelli M; Di Dio T; Minasi S; Donofrio V; Buccoliero AM; Gardiman MP; Pollo B; Diomedi Camassei F; Rossi S; Novello M; Giangaspero F; Arcella A; Gessi M; Buttarelli FR
    Am J Surg Pathol; 2021 Feb; 45(2):200-204. PubMed ID: 33428336
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
    Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
    Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant.
    Banan R; Christians A; Bartels S; Lehmann U; Hartmann C
    Acta Neuropathol Commun; 2017 Dec; 5(1):98. PubMed ID: 29246238
    [No Abstract]   [Full Text] [Related]  

  • 90. Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas.
    Kazarian E; Marks A; Cui J; Darbinyan A; Tong E; Mueller S; Cha S; Aboian MS
    Sci Rep; 2021 Jul; 11(1):14377. PubMed ID: 34257334
    [TBL] [Abstract][Full Text] [Related]  

  • 91. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
    Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
    Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM.
    Pathak P; Jha P; Purkait S; Sharma V; Suri V; Sharma MC; Faruq M; Suri A; Sarkar C
    J Neurooncol; 2015 Feb; 121(3):489-97. PubMed ID: 25479829
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
    Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
    Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Identification of genes functionally involved in the detrimental effects of mutant histone H3.3-K27M in Drosophila melanogaster.
    Berlandi J; Chaouch A; De Jay N; Tegeder I; Thiel K; Shirinian M; Kleinman CL; Jeibmann A; Lasko P; Jabado N; Hasselblatt M
    Neuro Oncol; 2019 May; 21(5):628-639. PubMed ID: 30715493
    [TBL] [Abstract][Full Text] [Related]  

  • 95. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
    Schwartzentruber J; Korshunov A; Liu XY; Jones DT; Pfaff E; Jacob K; Sturm D; Fontebasso AM; Quang DA; Tönjes M; Hovestadt V; Albrecht S; Kool M; Nantel A; Konermann C; Lindroth A; Jäger N; Rausch T; Ryzhova M; Korbel JO; Hielscher T; Hauser P; Garami M; Klekner A; Bognar L; Ebinger M; Schuhmann MU; Scheurlen W; Pekrun A; Frühwald MC; Roggendorf W; Kramm C; Dürken M; Atkinson J; Lepage P; Montpetit A; Zakrzewska M; Zakrzewski K; Liberski PP; Dong Z; Siegel P; Kulozik AE; Zapatka M; Guha A; Malkin D; Felsberg J; Reifenberger G; von Deimling A; Ichimura K; Collins VP; Witt H; Milde T; Witt O; Zhang C; Castelo-Branco P; Lichter P; Faury D; Tabori U; Plass C; Majewski J; Pfister SM; Jabado N
    Nature; 2012 Jan; 482(7384):226-31. PubMed ID: 22286061
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
    Ocasio JK; Budd KM; Roach JT; Andrews JM; Baker SJ
    Cancer Metastasis Rev; 2023 Jun; 42(2):367-388. PubMed ID: 37119408
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma.
    Shee K; Chambers M; Hughes EG; Almiron DA; Deharvengt SJ; Green D; Lefferts JA; Andrew AS; Hickey WF; Tsongalis GJ
    J Neurooncol; 2020 Jul; 148(3):473-480. PubMed ID: 32583303
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Genetic signature and treatment of pediatric high-grade glioma.
    Guidi M; Giunti L; Buccoliero AM; Caporalini C; Censullo ML; Galli L; Genitori L; Sardi I
    Mol Clin Oncol; 2021 Apr; 14(4):70. PubMed ID: 33732456
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.